| Literature DB >> 34522105 |
Juan Jiang1,2, Xia Wang3, Jian He3, Donglei Liao3, Xiaolu Deng3.
Abstract
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in immunocompromised children. Real-time polymerase chain reaction (PCR) is widely used for the diagnosis of PCP due to its good accuracy. However, the diagnostic performance of multiplex real-time PCR on sputum in children with PCP has never been explored.Entities:
Keywords: Pneumocystis jirovecii pneumonia; children; immunocompromised population; multiplex real-time polymerase chain reaction; sputum
Year: 2021 PMID: 34522105 PMCID: PMC8434890 DOI: 10.2147/IDR.S326814
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Baseline Clinical Characteristics, Laboratory Findings and Radiological Features of Pediatric PCP and Non-PCP Patients
| Characteristics (Median [IQR] or n [%]) | PCP Group (n=13) | Non-PCP Group (n=50) | |
|---|---|---|---|
| Age (years) | 5.7 (1.1–11.0) | 3.7 (1.1–7.0) | 0.391 |
| Male | 8 (61.5) | 33 (66.0) | 0.764 |
| Clinical symptoms | |||
| Fever | 11 (84.6) | 32 (64.0) | 0.155 |
| Cough | 9 (69.2) | 44 (88.0) | 0.099 |
| Expectoration | 2 (15.4) | 29 (58.0) | 0.006 |
| Shortness of breath | 11 (84.6) | 20 (40.0) | 0.004 |
| Immunocompromised conditions | |||
| Hematologic malignancy | 10 (76.9) | 15 (30.0) | 0.002 |
| Solid tumor | 0 (0) | 2 (4.0) | 0.464 |
| AIDS | 1 (7.7) | 0 (0) | 0.084 |
| Systemic use of corticosteroids | 11 (84.6) | 12 (24.0) | < 0.001 |
| Use of immunosuppressive agents | 9 (69.2) | 10 (20.0) | 0.001 |
| HSC transplantation | 0 (0) | 1 (2.0) | 0.607 |
| PaO2/FiO2 (mmHg) | 232 (180–288) | 260 (217–313) | 0.63 |
| WBC (×109/L) | 5.4 (1.6–9.3) | 7.6 (2.5–11.0) | 0.266 |
| Neutrophils (×109/L) | 3.9 (1.1–5.9) | 2.1 (1.0–6.3) | 0.832 |
| Lymphocytes (×109/L) | 0.5 (0.4–1.0) | 2.9 (0.6–4.6) | 0.007 |
| Hemoglobin (g/L) | 93 (78–106) | 111 (94–123) | 0.04 |
| Platelet (×109/L) | 160 (117–229) | 265 (142–391) | 0.079 |
| Serum BDG (ng/L) | (n=32)* | ||
| ≥ 80 | 10 (76.9) | 5 (15.6) | < 0.001 |
| ≥ 300 | 6 (46.2) | 0 (0) | < 0.001 |
| LDH (U/L) | 556 (376–677) | 298 (245–401) | < 0.001 |
| CRP (mg/L) | 14 (4–47) | 8 (2–66) | 0.688 |
| PCT (ng/mL) | 0.27 (0.08–0.60) | 0.29 (0.05–0.89) | 0.979 |
| Abnormalities on chest CT | |||
| Bilateral involvement | 13 (100) | 35 (70.0) | 0.027 |
| Multifocal involvement | 13 (100) | 36 (72.0) | 0.055 |
| Ground-glass opacity | 8 (61.5) | 10 (20.0) | 0.003 |
| Patchy shadowing | 6 (46.2) | 39 (78.0) | 0.024 |
| Consolidation | 1 (7.7) | 8 (16.0) | 0.446 |
| Interstitial patterns | 5 (38.5) | 2 (4.0) | 0.003 |
| Pleural effusion | 0 (0) | 11 (22.0) | 0.1 |
Note: (n=32)*, serum BDG was detected in 32 out of 50 non-PCP pediatric patients.
Abbreviations: IQR, interquartile range; AIDS, Acquired Immune Deficiency Syndrome; HSC, hematopoietic stem cells; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; BDG, (1,3)-β-D-glucan; LDH, lactate dehydrogenase; CRP, C-reactive protein; PCT, procalcitonin; CT, computed tomography.
Figure 1Representative chest CT images of a pediatric PCP patient (Case 13) on admission and discharge. (A) Chest CT images on admission showing diffuse ground-glass opacities in bilateral lungs. (B) Chest CT images on discharge showing that the majority of the bilateral pulmonary lesions were absorbed after anti-PCP treatment.
Multiplex Real-Time PCR Results on Sputum of Pediatric PCP Patients
| Case No. | Time from Sampling to Report (Days) | Time from Admission to Report (Days) | Pathogens Identified by Multiplex PCR |
|---|---|---|---|
| 1 | 1 | 2 | PJ, |
| 2 | 1 | 2 | PJ, |
| 3 | 1 | 2 | PJ, |
| 4 | 1 | 6 | PJ, CMV |
| 5 | 1 | 2 | PJ, CMV |
| 6 | 1 | 1 | PJ, |
| 7 | 1 | 1 | PJ, EBV |
| 8 | 1 | 1 | PJ, |
| 9 | 1 | 1 | PJ |
| 10 | 1 | 8 | PJ, EBV |
| 11 | 1 | 1 | PJ, CMV, EBV |
| 12 | 1 | 3 | PJ, |
| 13 | 1 | 14 | PJ, CMV, EBV, |
Abbreviations: PJ, pneumocystis jiroveci; CMV, cytomegalovirus; EBV, Epstein-Barr virus; S. pneumoniae, Streptococcus pneumoniae; M. pneumoniae, Mycoplasma pneumoniae; C. albicans, Candida albicans.
Figure 2Number of co-pathogens identified by multiplex real-time PCR in 13 pediatric patients.
Diagnostic Performance of Multiplex Real-Time PCR and Serum BDG Plus LDH in Pediatric PCP Patients
| Methods | PCP (n=13) | Non-PCP (n=50) | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|
| PCR | ||||||
| + | 13 | 1 | 100% | 98.0% | 92.9% | 100% |
| - | 0 | 49 | ||||
| BDG+LDH | ||||||
| + | 10 | 5 | 76.9% | 84.4% | 66.7% | 90.0% |
| - | 3 | 27 | ||||
| 0.066 | 0.021 | 0.082 | 0.024 |
Note: Serum BDG ≥ 80 ng/L and LDH ≥ 250 U/L were defined as positive.
Abbreviations: BDG, (1,3)-β-D-glucan; LDH, lactate dehydrogenase; PPV, positive predict value; NPV, negative predict value.
Impact of Multiplex Real-Time PCR on the Modifications of Antimicrobial Agents in Pediatric PCP Patients
| Indicators | PCP Patients (n [%]) |
|---|---|
| Modifications of antimicrobial agents | |
| Remove 1 agent | 2 (15.4) |
| Remove 2 agents | 1 (7.7) |
| Reduce antimicrobial spectrum | 5 (38.5) |
| Add 1 agent | 4 (30.8) |
| Add 2 agents | 1 (7.7) |
| Add TMP-SMZ | 6 (46.2) |
| Add Caspofungin | 1 (7.7) |
| Add Clindamycin | 1 (7.7) |
| Add antiviral agent | 5 (38.5) |
| No change | 3 (23.1) |
| Positive response to anti-PJ therapy | 13 (100) |
Notes: TMP-SMZ, trimethoprim-sulfamethoxazole; remove 1 (or 2) agent, the number of antimicrobial agent types reduced by 1 (or 2) after the report of mNGS results; add 1 (or 2) agent, the number of antimicrobial agent types reduced by 1 (or 2) after the report of mNGS results.
Abbreviation: PJ, pneumocystis jiroveci.